Atrica

Atreca was a clinical-stage biotechnology company that specialized in the discovery and development of novel antibody-based cancer immunotherapies. The company's unique approach involved analyzing the immune responses of 'elite responders'—patients who demonstrated exceptional clinical responses to cancer—to identify antibodies that target previously unrecognized tumor antigens. Its lead candidate, ATRC-101, was a monoclonal antibody designed to bind a ribonucleoprotein complex found in multiple solid tumor types. In late 2023, Atreca announced it would wind down operations and sell its core technology platform and clinical assets to Immunome, Inc.